inquiry@market.us
+1 718 874 1545 (International)
+91 78878 22626 (Asia)
Search...
All Reports
All Sectors
Who Trust Us
Home ➤ Life Science ➤ Pharmaceuticals ➤ Atopic Dermatitis Drugs Market
Atopic Dermatitis Drugs Market Analysis By Drug Class (Biologics, PDE-4 Inhibitor,
Corticosteroids, Calcineurin Inhibitors, and Other Drug Classes), By Route of
Administration (Injectable, Topical, Oral), By End-User (Hospital Pharmacies,
Online Pharmacies, and Retail Pharmacies), By Region and Companies - Industry
Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast
2023-2032
Published date: Oct 2024
Report ID: 65478
Number of Pages: 289
Inquiry Before Buying
Mention interested
topics/company profiles.
Format:
Enter Name
Overview
Table of Contents
Major Market Players
Request a Free Sample
Enter Email ID
-Select Country-
Quick Navigation
Report Overview
The Global Atopic Dermatitis Drugs Market size is expected to be worth around US$ 24.5
Billion by 2033, from US$ 10.5 Billion in 2023, growing at a CAGR of 9.1% during the forecast
Enter Phone Number
Enter Company Name
Submit
period from 2024 to 2033.
Atopic dermatitis is a type of eczema. It is a condition in which skin becomes red, dry, bumpy,
and itchy. Atopic dermatitis consists of allergic asthma, hay fever, food allergies, and
anaphylaxis.
The increasing significance of atopic dermatitis, the emergence of biologics, untapped
opportunities, and a strong pipeline are estimated to boost the growth of the market during
the forecast period 2023-2032. The significance of atopic dermatitis is increasing steadily.
According to the report in 2020, the significance of atopic dermatitis identified by the doctor in
patients which were ranged between 10.2% in Asian and 17.1% in Europe adults moreover 22.6%
and 0.96% in children.
The factors such as favorable reimbursement policies in developing countries, various
initiatives taken by the government, increasing awareness about the availability of treatments
Report ID
65478
Published Date
Oct 2024
Rating
★ ★ ★ ★ ★ (18)
add_shopping_cart Buy Now
for the disease, rapid technological advancement, and increase in funding with the
government support for R&D were also projected to boost the growth of the market during the
forecast period 2023-2032.
Trusted by more than 17382
organizations globally
Key Takeaways
The Atopic Dermatitis Drugs Market is projected to experience exponential growth
between 2022-2032 with compound annual growth at 9.1%.
Atopic Dermatitis (AD), or another form of Eczema, affects 10.2% to 17.1% of adult
population worldwide while between 0.96% to 22.6% affect children globally.
Biologics dominate with a 42% market share in 2022, attributed to government initiatives,
a robust pipeline, and high efficacy in severe cases.
Injectable drugs hold a 46% market share due to increased use, notably in pediatric
patients.
Hospital pharmacies lead distribution with various factors such as drug approvals and
government support driving growth.
Market drivers include the growing global significance of atopic dermatitis and the
increasing demand for biologics in dermatology.
Prolonged use of potent topical steroids can lead to side effects, acting as a potential
market restraint.
Opportunities arise from the development of novel pipeline drugs and favorable
reimbursement policies, particularly in developing countries.
North America dominates the market with a 52% revenue share, driven by favorable
reimbursement policies and the impact of the COVID-19 pandemic on hand atopic
dermatitis cases.
Drug Class Analysis
The biologics segment accounted for the largest revenue share of 42% in 2022. Over
conventional topical treatments, biologics have huge clinical advantages. Biologics are mainly
prescribed for severe cases when the patient is irresponsive to prior systemic therapies, mostly
for second or third-line treatment.
The dominance of the segment is owing to the increase in various government initiatives, the
availability of a robust pipeline of biologic drugs, new product launches, the availability of
treatments for the disease, and the increasing demand for biologics due to high efficacy. For
instance, a monoclonal antibody name nemolizumab is presently in the pipeline of Galderma
Laboratories, L.P., and it is being investigated for its use in atopic dermatitis.
Route of Administration Analysis
The injectable segment dominates the market with the highest revenue share of 46% and will
likely maintain its dominance over the forecast period. This is because of the increased use of
injectable products like Dupilumab.
There will be a shift in the use of therapeutics for atopic dermatitis in the near future as the use
of biologics is increasing gradually. There are only a few treatment options available for
pediatric patients with atopic dermatitis. So, biologics are being investigated for the treatment
of pediatric patients suffering from AD.
Distribution Channel Analysis
The hospital pharmacies segment dominated the market and is estimated to continue during
the forecast period. The factors such as approval of drugs, the high significance of atopic
dermatitis, increasing income levels of middle-class & poor families, and increase in prices of
drugs.
Furthermore, an increasing number of initiatives from different government bodies in
developing the infrastructures of hospitals as well as pharmacies are estimated to increase
the growth of the segment.
Key Market Segments
Based on Drug Class
Biologics
PDE-4 Inhibitor
Corticosteroids
Calcineurin Inhibitors
Other Drug Classes
Based on the Route of Administration
Injectable
Topical
Oral
Based on Distribution Channel
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Drivers
Increasing Significance of Atopic Dermatitis
The rising significance of atopic dermatitis medication globally is estimated to be the major
factor boosting the growth of the market for atopic dermatitis medications. Several individuals
are suffering from atopic dermatitis, which will results to propel the growth of the market over
the forecast period. Climatic circumstances, geographical location, age, lifestyle, gender,
socioeconomic level, individual behaviors, and inheritance all these factors impact the
significance of dermatological problems globally.
Increasing Demand for Biologics
Due to the increase in the use of biologic drugs in dermatology, the treatment of
dermatological disorders, mainly atopic dermatitis, has changed. By improving the overall
quality of life biologics, a positive response to atopic dermatitis have verified. Thus, the
demand for treatments for atopic dermatitis was increasing, and the pattern is likely to
continue over the forecast period. Till now, only one biologics product was permitted to use for
the treatment of AD; most of the other drugs were under phase II clinical studies and will likely
be approved soon.
Restraints
Side-Effects of Topical Steroids
If the topical steroid treatments last for less than four weeks, then they will be trouble-free and
risk-free. Frequent repetition of short doses of harsh steroids or long-term topical steroid use
may cause side effects on the body. Mild topical steroids have fewer side effects. The major
problem is the prolonged usage of potent steroids. The topical steroids have systemic as well
as local side effects. Local side effects refer to a particular area of the skin, while systemic side
effects refer to an issue that affects the entire individual body.
Opportunities
Rapid Development of Novel Pipeline Drugs
Rapid Development of Novel Pipeline Drugs, the High Significance of Atopic Dermatitis, and
Other Factors Create Numerous Opportunities for the Market.
The atopic dermatitis market is estimated to experience significant growth during the forecast
period. This is due to the rising number of AD industry, enhancement in demand for product
approvals and new biologics, and rapid development of novel pipeline drugs. Moreover,
different initiatives undertaken by governments with the aim of providing affordable and
better treatment are estimated to accelerate the growth of the market.
Likewise, the high significance of atopic dermatitis and the favorable reimbursement policies
in developing countries likely propel the market’s growth. Additionally, the increase in funding,
along with the rise in government support and various technological advancements, is
estimated to create different opportunities for the global atopic dermatitis drugs market
during the forecast period 2023-2032.
Trends
Biologics is the New Class Treatment in the Market
The new class of treatment in the market is biologics. The crucial factor that contributes to the
growth of the biologics segment is its targeted approach. The increasing rate of recurrence of
disease was driving various companies to invest in the expansion of novel biologics with high
effectiveness.
Biologics are not considered as first-line treatment, but it has safety, high efficacy, and a
targeted approach to treating the disease. That’s why dermatologists believe that it should be
considered the first choice for individuals who are suffering from atopic dermatitis.
Regional Analysis
North America Dominates the Global Atopic Dermatitis Drugs Market During the Forecast
Period
North America dominated the market with the highest revenue share of 52%. The key factors
that are responsible for the dominance of the region are the favorable reimbursement policies
and the presence of well-established R&D infrastructures. Additionally, in this sector, the
reimbursement and regulatory landscape is constantly developing to adapt to the fast
research progress.
The COVID-19 pandemic is estimated to positively impact the growth of the market. The
pandemic resulted in an increase in the frequency of hand-washing for the sanitation and
safety measures of the population to prevent the infection of the virus. But, frequent exposure
to water and soap has raised the cases of dry skin, which further results in the rise in cases of
hand atopic dermatitis.
Key Regions
North America
The US
Canada
Mexico
Western Europe
Germany
France
The UK
Spain
Italy
Portugal
Ireland
Austria
Switzerland
Benelux
Nordic
Rest of Western Europe
Eastern Europe
Russia
Poland
The Czech Republic
Greece
Rest of Eastern Europe
APAC
China
Japan
South Korea
India
Australia & New Zealand
Indonesia
Malaysia
Philippines
Singapore
Thailand
Vietnam
Rest of APAC
Latin America
Brazil
Colombia
Chile
Argentina
Costa Rica
Rest of Latin America
Middle East & Africa
Algeria
Egypt
Israel
Kuwait
Nigeria
Saudi Arabia
South Africa
Turkey
United Arab Emirates
Rest of MEA
Key Players Analysis
During the forecast period, the competitive landscape in the market is estimated to stay high
due to new product launches. To commercialize and develop new products, collaborations
and partnerships are being formed between players.
The competition is increasing in the market due to the lucrative nature of the market. Because
of this nature, it is attracting new players with innovative products in the market. For instance,
for atopic dermatitis adult and adolescent patients, AbbVie declared the extension of sDNA for
the review of RINVOQ in April 2021.
Market Key Players
Sanofi SA
Pfizer Inc.
AbbVie Inc.
Eli Lilly and Company
LEO Pharma Inc.
Novartis AG
Otsuka Pharmaceutical Co., Ltd.
Regeneron Pharmaceuticals Inc.
Other Key Players
Recent Developments
In September 2024: Eli Lilly announced the FDA approval of EBGLYSS (lebrikizumab-lbkz)
for treating moderate-to-severe atopic dermatitis in adults and children aged 12 and
older. This approval reflects the drug’s effectiveness, evidenced in Phase 3 studies where
EBGLYSS helped patients achieve significant skin clearance and relief from itching
symptoms. Following this regulatory nod, EBGLYSS will soon be available in the U.S.
market.
In June 2023: Sanofi reported positive Phase 2b trial results for amlitelimab, an
investigational anti-OX40-ligand monoclonal antibody. The study showed statistically
significant improvements in the Eczema Area and Severity Index (EASI) scores for
patients with moderate-to-severe atopic dermatitis, compared to placebo. Results
indicated a 61.5% reduction in EASI scores at week 16, which further improved to 64.4% at
week 24 for the highest dose of amlitelimab. These findings support the potential of
amlitelimab as a first and best-in-class treatment option for atopic dermatitis​.
In February 2023: Pfizer received U.S. FDA approval for the supplemental New Drug
Application (sNDA) of Cibinqo (abrocitinib) to include treatment for adolescents aged 12
to 18 years with refractory, moderate-to-severe atopic dermatitis. This expansion is
supported by results from the JADE TEEN clinical trial, which showed significant
improvement in skin clearance and itch reduction compared to placebo.
Report Scope
Report Features
Description
Market Value (2022)
US$ 10.5 Billion
Forecast Revenue
US$ 24.5 Billion
(2032)
CAGR (2023-2032)
9.1%
Base Year for Estimation
2022
Historic Period
2018-2022
Forecast Period
2023-2032
Report Coverage
Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive
Landscape, Recent Developments
Segments Covered
By Drug Class- Biologics, PDE-4 Inhibitor, Corticosteroids, Calcineurin
Inhibitors, and Other Drug Classes; By Application- Monitoring,
Treatment, Research, Healthcare, and Other Applications; and y
Distribution Channel- Hospital Pharmacies, Online Pharmacies, and
Retail Pharmacies.
Regional Analysis
North America – The US, Canada, & Mexico; Western Europe –
Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria,
Switzerland, Benelux, Nordic, & Rest of Western Europe; Eastern Europe
– Russia, Poland, The Czech Republic, Greece, & Rest of Eastern Europe;
APAC – China, Japan, South Korea, India, Australia & New Zealand,
Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, & Rest
of APAC; Latin America – Brazil, Colombia, Chile, Argentina, Costa Rica,
& Rest of Latin America; The Middle East & Africa – Algeria, Egypt, Israel,
Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab
Emirates, & Rest of MEA.
Competitive Landscape
Sanofi SA, Pfizer Inc., AbbVie Inc., Eli Lilly and Company, LEO Pharma Inc.,
Novartis AG, Otsuka Pharmaceutical Co., Ltd., Regeneron
Pharmaceuticals Inc., and Other Key Players.
Customization Scope
Customization for segments, region/country-level will be provided.
Moreover, additional customization can be done based on the
requirements.
Purchase Options
We have three licenses to opt for Single User License, Multi-User
License (Up to 5 Users), Corporate Use License (Unlimited User and
Printable PDF)
Atopic Dermatitis Drugs Market
Published date: Oct 2024
add_shopping_cart Buy Now
get_app Download Sample
Related Reports
Connected Drug Delivery Devices Market
Atopic Dermatitis Drugs Market
Erectile Dysfunction Drug Market
Myelodysplastic Syndrome Drugs Market
Smart Drug Delivery System Market
Injectable Drug Delivery Market
Cimzia (certolizumab) Drug Market
Our Clients
SINGLE USER
MULTI USER
$6,000
$8,000
CORPORATE USER
$10,000
$3,999
$5,999
$6,999
USD / PER UNIT
USD / PER UNIT
USD / PER UNIT
SAVE 24%
SAVE 28%
SAVE 32%
No
up to 10 hrs work
up to 30 hrs work
1 User
2-5 User
Unlimited
up to 20 hrs
up to 40 hrs
up to 50 hrs
Up to 20% off on next purchase
Up to 25% off on next purchase
Up to 30% off on next purchase
Buy Now ($ 3,999)
Buy Now ($ 5,999)
Buy Now ($ 6,999)
e-Access
Report Library Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization
Accessibility
Analyst Support
Benefit
Lexington Avenue, Suite
location_on 420
300 New York City, NY 10170,
United States
phone +1 718 874 1545 (International)
phone +91 78878 22626 (Asia)
email inquiry@market.us
Find Help
Explore
Contact Us
About Us
How to Order
All Reports
Legal
Privacy Policy
Refund Policy
Frequently Asked Questions
Terms and Conditions
© 2025 Market.Us. All Rights Reserved.
All Sectors
Infographics
Statistics and Facts
Companies
Secured Payment Options